



## **ADDING BENCH STRENGTH TO A TALENTED TEAM**



**Scott Kelly** Managing Director, **CEO** Australia



- ◆ 28+ years of global wealth management and asset management experience.
- Prior to joining RAM, Scott was a Managing Director and Head of Investment Products and Services at UBS Wealth Management Australia. overseeing \$24BN AUM.



William Gray Head of Real Estate



**Matthew Strotton Head of Funds** Management - Real Estate



**Doug Rapson** Director **Asset Management** 



**Ben Bochow** Chief Financial Officer -Real Estate

- 20+ years experience in markets, real estate including 13 years in institutional real estate funds management.
  - Prior to joining RAM, Will was a fund manager at LaSalle Investment Management and portfolio analyst at QIC.
- ♦ 25+ years experience in global real estate markets across capital transactions, development, product and funds investment management.
- joining RAM, Prior to Matthew Global was Director and Head of Funds Management at QIC Global Real Estate, with responsibility for Australian United States and portfolios.
- ♦ 10+ years of experience in Commercial Real Estate.
- Prior to joining RAM, Doug was a Senior Executive in Capital Markets - Retail Investments at JLL direct involvement in more than \$1.7BN in real estate transactions.
- ♦ 16+ years in real estate finance, having worked for private equity institutions in Australia and the UK.
- ◆ Prior to joining RAM, Ben was Assistant VP of Finance at Curzon Advisers in London, overseeing the Accounting and Operations functions for RE portfolios across Europe.

16 **OTHER REAL ESTATE PROFESSIONALS** 50+ **SUPPORT STAFF** 



Investment **Management** 



**Operations** 



**Client Solutions** 



Sales & Marketing



**Finance** 



IT & Facilities



**Legal Compliance** & Risk



Human Resources

### **HIGHLIGHTS**



## **Portfolio**



67%

Externally revalued as at 31-December-2021



\$44M+

Recently secured off market healthcare transactions



50%

Medical income exposure<sup>1</sup>



\$200M+

Ongoing activated value-add pipeline



## **Financial**



+7.4%

NTA growth since listing<sup>2</sup>



25.8%

Gearing<sup>3</sup>



1.09c

December-2021 DPU In line with guidance



4.0c

20-October-2021 to 30-Jun-2022 Guidance increase



#### STRENGTHENING THE INVESTMENT CASE

A unique portfolio of medical and essential retail real estate, with exposure to essential services tenants, long-WALE profile and the opportunity for capital growth.

High quality, ◆ 11 settlements undertaken during December-2021 quarter, all high-quality medical acquisitions, equating to \$128m. geographically Further off-market medical acquisitions secured, overall fund income rebalanced upwards, now at strategic weighting diversified to medical at 50%. portfolio Geographically diversified Australia wide portfolio with assets across 6 states & territories. • 94% of fund income from essential service tenants. **Defensive income** 85% of fund income is exposed to annual rental escalations via fixed or CPI reviews. profile<sup>2</sup> 31% of fund income exposed to CPI or CPI indexed annual rental escalators. 46% fund income exposed to fixed annual rental escalators, WARR of 3.4%. Progression of value-add pipeline (\$200m+ over a five-year period) with increased scope driven by Organic growth amplified development pipeline across medical portfolio. through value-Provides continued growth of asset base via strategic developments with yield-on-costs, on-average, greater than add pipeline core capitalisation rate of assets under development. delivery Fresh medical acquisitions secured via capital recycling initiative crystallising an accretive earnings outcome to REP. REP offers unparalleled exposure to high quality medical real estate assets, an asset class that is currently difficult to access for ASX investors. Unique exposure 94% of medical property portfolio is associated with primary healthcare assets with a strong weighting to private / to high quality day hospitals. medical real estate • Favourable long-term secular trends in connection with the increasing investor interest in the sector is expected to provide continued tailwinds for asset valuations. ◆ 7.4% increase in NTA to 31-December-2021, 67% of portfolio has been externally revalued since listing. Relative value Non-core divestment of Coles Gunnedah indicates material upside in carrying value, circa 140bps cap rate compression achieved Acquisition Uniquely placed to source attractive medical acquisition opportunities, as demonstrated by high portion of off-market

transactions across multiple jurisdictions and through various private and institutional vendors.

- 1. Pro forma includes capital transactions executed post 31 December 2021.
- 2. Based on Gross Property Income as per 31 December 2021.

pipeline





Well positioned for a higher inflationary environment





The Funds income has a strong exposure to annual CPI and CPI indexed reviews.

**46%** of fund income exposed to fixed reviews with a high WARR of 3.4%<sup>1</sup>.

35%<sup>1</sup> of formula derived income, access to turnover rent, is in or expected to hit turnover rent territory providing strong in-built inflation hedge.

**58%** of portfolio exposed to net leases providing protection to inflation impacts on property outgoings.





### Essential service exposure provides resilience



**99**% 四

Robust cash collections across the portfolio at 98.5% for the HY22.


Occupancy remains strong reflecting 99%<sup>1</sup>.




7.3<sub>yrs</sub>

94% of fund income has exposure to essential service and medical based income which remains highly resilient. 50% fund income exposure to medical income achieved.<sup>2</sup>

Long WALE solution of 7.3 years<sup>2</sup> which has increased since PDS issuance with limited specialty leasing risk exposure over the next 24 months.



<sup>2.</sup> Pro forma includes capital transactions executed post 31 December 2021. PDS WALE was 7.1 years.



High quality and diversified tenant mix with organic growth



Top 20 tenants encompass 55% of fund income<sup>1</sup>.



Strategic relationships being actively leveraged into real investment opportunities - 70% of our top 20 tenants' income exposure.

Rank	Tenant	Category	% of Income
1	health care	Medical	10.9%
2	Woolworths Group	Essential Retail	10.0%
3	coles	Essential Retail	7.1%
4	ST JOHN OF GOD  Health Care	Medical	2.3%
5	Wesfarmers	Essential Retail	2.3%
6	Avantis HEALTH CENTRE	Medical	2.3%
7	<b>IGR</b>	Essential Retail	2.3%
8	PIPN MEDICAL CENTRES	Medical	2.3%
9	endeavour group	Essential Retail	2.2%
10	Fertility Clinic	Medical	2.1%

Rank	Tenant	Category	% of Income
11	PANACEUM	Medical 🕕	1.8%
12	MIAMI PRIVATE HOSPITAL	Medical	1.6%
13	CHEMIST	Medical 🕕	1.3%
14	CAPITAL	Medical 🕕	1.2%
15	DR.SC PE	Medical 🕕	1.1%
16	//Amcal+	Medical 🕕	1.1%
17	Spectrum Health	Medical 🕕	1.1%
18	bigfresh	Essential Retail	1.0%
19	Rad Corporate Radiology	Medical 🕕	1.0%
20	TOP END MEDICAL CENTRE	Medical 🕕	0.9%

<sup>1.</sup> Pro forma includes capital transactions executed post 31 December 2021.

Relative value proposition shining through



67% portfolio externally revalued



WACR now at 5.64% down from 5.85% (21bps compression)

Property type	WACR at IPO	WACR at Dec 21	WACR mvt
Medical	5.60%	5.34%	(0.26%)
Essential retail	6.02%	5.87%	(0.15%)
Total	5.85%	5.64%	(0.21%)

Portfolio	Properties	31 Dec 2021 book value (\$m)	% Portfolio	Reval uplift (%)
Medical	20	318.6	43.2%	5.46%
Essential Retail	13	418.3	56.8%	4.21%
Total	33	736.9	100.0%	4.75%



7.4% increase in NTA



Both portfolio sectors are contributing to valuation gains, reinforcing selection of underlying fund strategy



Essential retail divestment (Coles Gunnedah) represents further 140bps cap rate compression, indicating relative value potential of essential retail portfolio



Further NTA upside potential with balance of the portfolio to be externally revalued at or around June-2022

### Active portfolio management



Unsolicited offer provided opportunity to divest asset at a circa 140 bps compression on the prior independent cap rate, circa 25% increase in underlying value.



Divestment proceeds provided sufficient liquidity to crystallize accretive off-market medical acquisitions.



New medical acquisitions offering primary healthcare solutions and long WALEs, all with net lease exposures and annual rent review structures.



Accretive earnings outcome whilst maintaining a modest pro forma gearing level and ability to continue with value add program.



\$35.1m purchase price 4.54% cap rate 12.0 year WALE



\$8.87m purchase price 5.75% cap rate 8.0 year WALE



\$20.25m sale price 5.35% cap rate 3.9 year WALE

## Active portfolio management

	Existing Portfolio		Enhanced Portfolio		
	At IPO	31 Dec 21	Acquisitions	Divestments	Post Transactions
Number of Properties	33	33	3	1	35
Total Property Value	\$706.3M	\$736.9M	\$43.97M	\$20.25M	\$760.6M
WACR	5.85%	5.64%	4.80%	5.35%	5.60%
Gross Lettable Area (GLA)	126,122 sqm	127,081 sqm	3,327 sqm	5,561 sqm	124,847 sqm
Occupancy	99%	99%	100%	100%	99%
WALE	7.1 year	7.0 year	11.0 year	3.9 year	7.3 year
Essential Services / Medical Income	94%	94%	100%	93%	94%
Medical Income	45%	46%	100%	0%	50%
Essential Retail Income	48%	48%	0%	93%	45%
Proportion of income subject to annual rental increases	85%	85%	100%	44%	87%



Increase % of fund income toward medical related tenure



Increase in fund overall WALE



Increase the fund's exposure to net leases



Increase the fund's exposure to leases with annual rent escalators



Exit assets with low growth and poor cost recovery mechanisms



## **VALUE-ADD PIPELINE**



Good progress on activated and ongoing value-add pipeline



Increased opportunity of \$200m+ over 5 years



Improved exposure to land rich medical assets



Strong yield on cost outcomes expected - accretive in nature





Miami Private Hospital Proposed Development



North West Private Hospital Extension



Ballina Central 50% Milestone Achieved with Zarraffas Completed



# **VALUE-ADD PIPELINE – PROGRAM UPDATE**

Project Overvie	ew .	Development Update			
Property Name	Sector	Phase 1 – Development Approval	Phase 2 – Income Pre-commitment	Phase 3 – Construction^	
Immediate Value-Add Projects					
Ballina Central	Essential Retail			•	
Keppel Bay Plaza - Stage 1	Essential Retail	•		•	
Coles Gunnedah	Essential Retail	•	•	•	
Coomera Square	Essential Retail	•	•	•	
Springfield Fair	Essential Retail	•	•	•	
Windaroo Village	≡ Essential Retail	•	•	•	
North Lakes	Essential Retail	•	•	0	
Keppel Bay Plaza - Stage 2	Essential Retail	•	•	•	
Mayo Private Hospital	Medical	•	•	0	
Miami Private Hospital	Medical	•	0	0	
Willetts Health Precinct	Medical	•	0	0	
North West Private Hospital	Medical	•	•	0	
Ballina Central	📜 Essential Retail	•		0	
Coles Rutherford	<u></u> Essential Retail	•	•	0	
Total Project Costs – Approx.	\$135 Million				
Medium Term Strategic Value Add Proje	cts				
Mowbray Marketplace	Essential Retail	$\circ$	0	0	
Yeronga Village	Essential Retail	•	0	0	
Dubbo Private Hospital	Medical	•		0	
Total Project Costs – Approx.	\$100 Million				
Total Project Costs – Approx.	\$200+ Million				



## **FINANCIAL RESULTS**



Property income growth and revaluations driving revenue performance.



Operational performance driving FFO in line with expectations.



December distribution in line with FY22 guidance.



7.4% increase in NTA.

	HY22 <sup>1</sup> (Oct 21 – Dec 21)
	\$'m
Property Income	9.9
FV Increase	33.1
Other Income	0.4
Total Revenue	43.4
Property Expenses	(3.0)
IM Fees	(0.9)
Finance Costs	(1.3)
Other Expenses	(11.0)
Total Expenses	(16.2)
Net Profit/(Loss)	27.2
FFO	5.5
NTA per security (\$)	1.01

### **BALANCE SHEET AND CAPITAL MANAGEMENT**



Strong balance sheet management with gearing within target range.



Debt headroom to pursue active portfolio management and accretive opportunities.



Opportunistic divestment funded will partially fund acquisitions (post period).



Significant covenant headroom.

Key metrics	Pro Forma <sup>1</sup>	31 Dec 2021
Total drawn debt (\$m)	253.1	224.8
Gearing <sup>3</sup> (%)	28.6	25.8
Cost of debt <sup>2</sup> (%)	2.2	2.2
Weighted average debt expiry	2.6 years	2.6 years
Proportion hedged (%)	50.0%	51.2%

<sup>1.</sup> Pro forma metrics assuming settlement of capital transactions as at 31 December 2021.

<sup>2.</sup> Average effective interest rate for the period includes margin, undrawn line fees, swap costs fees and capitalised interest.

<sup>3.</sup> Gearing is defined as ratio of total net borrowing over total assets less cash.

#### SUMMARY AND OUTLOOK



**Strong execution** of the plan outlined in the pre-IPO presentations, meeting or exceeding guidance. Recent transactions mean we have moved to the target weight of 50% medical exposure whilst increasing DPU guidance and maintaining gearing at lower end of range.



**Natural inflation hedge** with a highly secure cashflow profile, 94% of income derived from essential services and medical, a 7.3 year WALE, 99% occupancy and over 87% of portfolio by income with exposure to annual rent escalations.<sup>1</sup>



**Embedded growth** from identified and activated pipeline now estimated at over \$200M+. Value-add developments delivered by team with strong track record.



Continued focus by management to grow income through development pipeline and portfolio enhancements with a resolute commitment to essential services.

<sup>1.</sup> Pro forma includes capital transactions executed post 31 December 2021.



# **INCOME STATEMENT**

REVENUE		HY22 (Oct 21 – Dec 21)
Gross property income	\$m	9.9
Unrealised gain on fair value investment properties	\$m	33.1
Unrealised gain on fair value derivatives	\$m	0.4
Interest income	\$m	0.0
Total revenue	\$m	43.4

EXPENSES		
Direct property expenses	\$m	(2.9)
Transaction costs	\$m	(10.8)
Responsible entity fees	\$m	(0.9)
Finance costs	\$m	(1.3)
Other admin expenses	\$m	(0.2)
Provisions for Covid abatements	\$m	(0.1)
Total expenses	\$m	(16.2)
Statutory net profit	\$m	27.2
Funds from operations (FFO)	\$m	5.5
Weighted average securities on issue	m	521.1
FFO per security	cps	1.06
Distributions	\$m	5.7
Distribution per security	cps	1.09
Net tangible assets per security	\$	1.01

# **FFO RECONCILIATION**

	HY22 (Oct 21 – Dec 21) \$'000
Net profit after tax for the period	27,217
Adjusted for: Reversal of straight-line lease revenue recognition	(194)
Reversal of unrealised fair value (gain) on investment properties	(33,105)
Reversal of unrealised fair value (gain) on derivatives	(435)
Add back amortised borrowing costs	377
Add back amortised leasing costs and tenant incentives	711
Add back transaction costs	10,782
Add back rent free and abatements	190
Funds From Operations (FFO)	5,543
Distribution declared	5,690
Weighted securities on issue (million)	521.1
FFO (cents per security)	1.06
Distribution per security (cents per security)	1.09
FFO payout ratio (% of FFO)	102.6

# **CONSOLIDATED BALANCE SHEET**

	31 Dec 2021 \$' <b>000</b>
Cash and equivalents	31,469
Investment properties	736,893
Other assets	12,065
Total assets	780,427
Borrowings	222,382
Distributions payable	5,690
Other liabilities	20,789
Total liabilities	248,861
Net assets	531,566
Stapled securities on issue (thousands)	521,084
NTA per security (\$)	1.01

#### IMPORTANT INFORMATION

The information contained herein does not have any regard to the specific investment objectives, financial situation or the particular needs of any person. The information is this presentation is not intended to be personal financial advice. This material has been prepared by RAM Property Funds Management Ltd (ABN 28 629 968 163; AFSL 514484) for informative and illustrative purposes only and should not be construed as legal, tax, investment or other advice. This material does not constitute an offer to sell, or the solicitation of an offer to buy, any securities. All investments involve the potential for a loss of capital. Prospective investors should seek separate, independent financial and professional advice if required prior to making an investment to assess the suitability, lawfulness and risks involved. The statements in this Presentation are not intended to be complete or final and are qualified in their entirety by reference to the final Half Yearly Reporting Documents for FY21 lodged with the ASX (the "Half Yearly Results"). Indications of, and guidance on, future earnings and financial position and performance and activities are "forward-looking statements". Due care and attention has been used in the preparation of any forward-looking statements. While RAM Group believe that there is a reasonable basis for the forward-looking statements such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the RAM Group, that may cause actual results to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. Except as required by law, the Group does not undertake any obligation to publicly update or review any forward looking statements, whether as a result of new information or future events. Past performance is not necessarily indicative of future performance. In the event that the descriptions or terms described herein are inconsistent with or contrary to the descriptions in or terms of the Half Yearly Results, the Half Yearly Results will prevail. GENERAL ADVICE WARNING the information in this presentation does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions.